LESS : Single-arm study to de-escalate adjuvant endocrine therapy duration in women with HR+ HER2- breast cancer at very low risk of metastasis

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-514480-26-00

Acronym

UC-BCG-2103

Enrollment

776

Registered

2024-06-05

Start date

2022-10-12

Completion date

Unknown

Last updated

2025-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post-menopausal women with localized luminal A breast cancer and considered at low risk of metastatic relapse

Brief summary

Distant relapse–free interval (DRFI) defined as the time from date of beginning of hormonotherapy to the date of first event of distant recurrence or breast cancer related death.

Detailed description

Invasive disease-free survival (iDFS), Invasive breast cancer–free survival (iBCFS), Breast cancer specific survival (BCSS), Overall survival (OS), Quality of life, Safety: Adverse Events will be graded according to NCI-CTCAE v5.0, Distant Disease-Free Survival (DDFS)

Interventions

DRUGEXEMESTANE

DRUGANASTROZOLE

DRUGLETROZOLE

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Distant relapse–free interval (DRFI) defined as the time from date of beginning of hormonotherapy to the date of first event of distant recurrence or breast cancer related death.	—

Secondary

Measure	Time frame
Invasive disease-free survival (iDFS), Invasive breast cancer–free survival (iBCFS), Breast cancer specific survival (BCSS), Overall survival (OS), Quality of life, Safety: Adverse Events will be graded according to NCI-CTCAE v5.0, Distant Disease-Free Survival (DDFS)	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026